Singapore markets open in 4 hours 6 minutes

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.30000.0000 (0.00%)
As of 03:54PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.3000
Bid2.3000 x 1800
Ask2.3100 x 2200
Day's range2.2100 - 2.3700
52-week range1.4300 - 10.9910
Avg. volume4,492,047
Market cap256.137M
Beta (5Y monthly)0.68
PE ratio (TTM)N/A
EPS (TTM)-2.5500
Earnings date04 Mar 2024 - 08 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.00
  • GlobeNewswire

    Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

    – Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status– – Treatment resulted in a 37% reduction in the risk of death versus chemotherapy alone – -– LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy and will be available to NPC patients in the U.S. in January 2024 – REDWOO

  • Motley Fool

    Why Coherus BioSciences Was Plummeting This Week

    A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of mid-afternoon Friday, according to data compiled by S&P Global Market Intelligence, the healthcare company's share price had fallen by a steep 56% week to date. On Monday after market close, Coherus unveiled a set of third-quarter results that, despite a double-digit revenue increase, missed analyst estimates.

  • Motley Fool

    Why Coherus Biosciences Stock Dropped Today

    Shares of Coherus Biosciences (NASDAQ: CHRS) were down by about 30% as of 3:25 p.m. ET Tuesday after the company announced disappointing third-quarter results and lowered its full-year guidance. It generated $40 million of net sales of Cimerli, which treats retinal conditions -- up 50% from the prior quarter -- and $1.4 million from arthritis treatment Yusimry. Coherus highlighted its recently resubmitted biologic license application for Udenyca OnBody, its on-body injector presentation of Udenyca, after the completion and satisfactory resolution of a Food and Drug Administration (FDA) review of inspection findings at a third-party filler.